LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Top 10 US Biomedical Research Institutions Involved in Drug Development

By LabMedica International staff writers
Posted on 23 Feb 2014
As Big Pharma companies are increasingly slashing their R&D spending, academic research institutions must play a key role in the drug development process, particularly on the preclinical research and drug discovery side.

Whereas many of the research institutions are still doing ample fundamental science research, interest seems to be growing among the universities in repurposing existing drugs or those that never made it into the marketplace because of safety problems, according to recent market research.

FierceBiotech (Washington DC, USA), an online drug development industry publication that monitors biopharmaceutical deals, the US Food and Drug Administration (FDA), and clinical trials, recently reviewed some of the best research institutions in the United States and ranked by them by their level of funding from the US National Institutes of Health (NIH; Bethesda, MD, USA), the largest funder of biomedical research worldwide.

In 2013, funding for biomedical research at these institutions took a hit from sequestration on top of years of budget slashes to the NIH. Out of 10, 7 of those on the list (shown below) lost funding in US fiscal 2013 compared to the same period in 2012. Stanford University, the University of North Carolina at Chapel Hill, and the University of California, San Francisco, were the only 3 among the top 10 to receive a slight cash influx in NIH funding from 2012 to 2013. A 2014 spending bill passed in January 2014 will restore USD 1 billion to NIH compared to fiscal year 2013 postsequester, but that is still below presequester funding levels.

The top ten instituitions: 1. Johns Hopkins University (Baltimore, MD); 2. University of California, San Francisco; 3. University of Washington (Seattle, WA, USA); 4. University of Pennsylvania (Philadelphia); 5. University of Michigan (Ann Arbor); 6. University of Pittsburgh (PA); 7. University of North Carolina at Chapel Hill; 8. University of California, San Diego; 9. Stanford University (Stanford, CA), and 10. Duke University (Durham, NC).

FierceBiotech is a publication of FierceMarkets, a division of Questex Media Group, LLC.

Related Links:

FierceBiotech 
National Institutes of Health


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more